• Abbott Laboratories (NYSE:ABT) reported an EPS of $1.09, surpassing estimates and showing improvement from the previous year.
• The company's revenue of $10.36 billion fell slightly short of estimates, but it reaffirmed its annual guidance with robust growth projections.
• Abbott's financial health is solid, with a P/E ratio of approximately 17.08 and a debt-to-equity ratio of approximately 0.32, indicating moderate debt levels and strong market valuation.

Abbott Laboratories, listed as NYSE:ABT, is a global healthcare company known for its diverse range of products, including medical devices, diagnostics, and nutritional products. The company competes with other major healthcare firms like Johnson & Johnson and Medtronic. Abbott's focus on innovation and quality has helped it maintain a strong position in the healthcare industry.

On April 16, 2025, Abbott reported earnings per share (EPS) of $1.09, surpassing the estimated $1.07. This performance marks an improvement from the previous year's EPS of $0.98, as highlighted by Zacks. Despite this earnings beat, the company's revenue of $10.36 billion fell slightly short of the estimated $10.41 billion.

Abbott's stock experienced a slight decline following the release of its first-quarter results, with a premarket trading price of $125.77. Despite the sales miss, the company reaffirmed its annual guidance, projecting adjusted earnings between $5.05 and $5.25 per share and organic sales growth of 7.5% to 8.5%. Analysts had forecasted earnings of $5.15 per share and total sales of $44.41 billion for the year.

The company's strong performance in the first quarter was driven by robust demand for its diabetes care products and other medical devices. This focus on the medical device segment has been a key growth area for Abbott. The company's price-to-earnings (P/E) ratio of approximately 17.08 indicates the market's valuation of its earnings, while its price-to-sales ratio of about 5.46 reflects the market's valuation of its revenue.

Abbott's financial health is further supported by its debt-to-equity ratio of approximately 0.32, suggesting a moderate level of debt relative to equity. The company's current ratio of about 1.67 indicates its ability to cover short-term liabilities with short-term assets. Additionally, Abbott's enterprise value to sales ratio is around 5.64, and its enterprise value to operating cash flow ratio is approximately 27.65, providing insights into its valuation relative to sales and cash flow.